Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + Chemo for Resectable Pancreatic Cancer
NCT06172036Phase 2Not yet recruiting
- Sponsor
- Zhejiang University
- Start
- Jan 2024
- Primary completion
- Jan 2026
- Modality
- Immune Checkpoint Inhibitors
01
Overview
Phase 2, randomised, open-label trial of adebrelimab in pancreatic cancer (PC) (3 arms), sponsored by Zhejiang University. Primary endpoint: 12-month Event-Free Survival Rate. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06172036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06172036.